SG11202002528SA - Radioactive drug - Google Patents
Radioactive drugInfo
- Publication number
- SG11202002528SA SG11202002528SA SG11202002528SA SG11202002528SA SG11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA
- Authority
- SG
- Singapore
- Prior art keywords
- radioactive drug
- radioactive
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017185484 | 2017-09-26 | ||
| PCT/JP2018/035786 WO2019065774A1 (en) | 2017-09-26 | 2018-09-26 | Radioactive drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002528SA true SG11202002528SA (en) | 2020-04-29 |
Family
ID=65903027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002528SA SG11202002528SA (en) | 2017-09-26 | 2018-09-26 | Radioactive drug |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11167050B2 (en) |
| EP (1) | EP3689892A4 (en) |
| JP (1) | JP7207740B2 (en) |
| KR (1) | KR20200056979A (en) |
| CN (1) | CN111065646B (en) |
| CA (1) | CA3086454A1 (en) |
| SG (1) | SG11202002528SA (en) |
| WO (1) | WO2019065774A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY195529A (en) | 2016-11-18 | 2023-01-30 | Astellas Pharma Inc | Novel Anti-Human MUC1 Antibody Fab Fragment |
| TWI795415B (en) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | A novel anti-human CEACAM5 antibody Fab fragment |
| SG11202009990UA (en) * | 2018-04-16 | 2020-11-27 | Nihon Mediphysics Co Ltd | Modified antibody and radioactive metal-labelled antibody |
| WO2020093055A2 (en) | 2018-11-02 | 2020-05-07 | Indi Molecular, Inc. | Peptide libraries with non-canonical amino acids |
| KR20210113202A (en) | 2019-01-07 | 2021-09-15 | 아스텔라스세이야쿠 가부시키가이샤 | Complex comprising a ligand, a spacer, a peptide linker and a biological molecule |
| AU2021230210A1 (en) | 2020-03-04 | 2022-09-22 | Kyoto University | Compound and radioactive labeling compound |
| WO2022098745A1 (en) * | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| AU2022228911A1 (en) | 2021-03-04 | 2023-09-21 | Kyoto University | Compound and radioactive labeling compound |
| CN114685389B (en) * | 2022-03-04 | 2023-10-27 | 复旦大学附属中山医院 | PET imaging agent based on Michael addition, preparation method and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005047821A (en) * | 2003-07-30 | 2005-02-24 | Nihon Medi Physics Co Ltd | Diagnostic or therapeutic medicine using cyclopentadienyl carbonyl group-containing radiactive compound |
| JP6164556B2 (en) * | 2011-12-01 | 2017-07-19 | 国立大学法人 千葉大学 | Drug for producing radiolabeled polypeptide with reduced nonspecific renal accumulation |
| JP6410339B2 (en) * | 2013-03-25 | 2018-10-24 | 国立大学法人千葉大学 | Radionuclide labeled octreotide derivatives |
| JP6966741B2 (en) | 2016-03-01 | 2021-11-17 | 国立大学法人千葉大学 | Radioactive labeling drug |
-
2018
- 2018-09-26 KR KR1020207003700A patent/KR20200056979A/en not_active Application Discontinuation
- 2018-09-26 EP EP18861877.1A patent/EP3689892A4/en active Pending
- 2018-09-26 US US16/648,703 patent/US11167050B2/en active Active
- 2018-09-26 WO PCT/JP2018/035786 patent/WO2019065774A1/en unknown
- 2018-09-26 JP JP2019545585A patent/JP7207740B2/en active Active
- 2018-09-26 CA CA3086454A patent/CA3086454A1/en active Pending
- 2018-09-26 CN CN201880055323.7A patent/CN111065646B/en active Active
- 2018-09-26 SG SG11202002528SA patent/SG11202002528SA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2019065774A1 (en) | 2021-01-28 |
| CN111065646B (en) | 2023-05-30 |
| KR20200056979A (en) | 2020-05-25 |
| US11167050B2 (en) | 2021-11-09 |
| CA3086454A1 (en) | 2019-04-04 |
| EP3689892A4 (en) | 2021-05-12 |
| CN111065646A (en) | 2020-04-24 |
| US20200268913A1 (en) | 2020-08-27 |
| EP3689892A1 (en) | 2020-08-05 |
| WO2019065774A1 (en) | 2019-04-04 |
| JP7207740B2 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266017A (en) | Pharmaceutical compounds | |
| GB201612092D0 (en) | Pharmaceutical compounds | |
| GB201617758D0 (en) | Pharmaceutical compounds | |
| SG11202002528SA (en) | Radioactive drug | |
| IL264415B (en) | Pharmaceutical compounds | |
| HUE052107T2 (en) | Pharmaceutical compounds | |
| GB201612095D0 (en) | Pharmaceutical compounds | |
| GB201709652D0 (en) | Pharmaceutical compounds | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201704714D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| GB201617454D0 (en) | Pharmaceutical compounds | |
| IL269239A (en) | Pharmaceutical combination comprising ponesimod | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| ZA201805549B (en) | Syringe | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| GB201703876D0 (en) | Pharmaceutical combinations | |
| GB201617871D0 (en) | Pharmaceutical compounds | |
| EP3431079C0 (en) | Tablet | |
| SI3728220T1 (en) | Pharmaceutical compounds | |
| GB201715316D0 (en) | Medicine Etc | |
| ZA201806493B (en) | Insecticidal tablet | |
| GB201717005D0 (en) | Pharmaceutical compounds | |
| GB201711704D0 (en) | Pharmaceutical compounds | |
| GB201716001D0 (en) | EG tipex etc capsules |